Geron | GERN - Ebitda

Stock Price
1.38
Daily Change
-0.03 -1.79%
Monthly
1.10%
Yearly
-68.82%
Q3 Forecast
1.39

Geron reported $-7550000 in EBITDA for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 555.2M
Cash and Equivalent USD 79.6M
Cost of Sales USD 1.19M
Current Assets USD 505.6M
Current Liabilities USD 64.28M
Debt USD 121.84M
EBIT USD -12.45M
EBITDA USD -7.55M
Employees 229
EPS Earnings Per Share USD -0.02
Equity Capital and Reserves USD 259.53M
Gross Profit on Sales USD 47.85M
Interest Expense on Debt USD 8.52M
Interest Income USD 4.66M
Loan Capital USD 118.99M
Market Capitalization USD 846.3M
Net Income USD -16.38M
Operating Expenses USD 61.49M
Operating Profit USD -12.45M
Ordinary Share Capital USD 636.92M
Pre-Tax Profit USD -16.38M
Sales Revenues USD 49M
Selling and Administration Expenses USD 38.56M
Stock USD 69.13M
Trade Creditors USD 8.23M
Trade Debtors USD 39.36M

Ebitda Change Date
Amgen USD 3.6B 147M Jun/2025
Bio Techne USD 115.58M 47.73M Jun/2025
Cassava Sciences USD -45174000 15.95M Jun/2025
Cytokinetics USD -153331000 16.67M Mar/2025
Exelixis USD 220.92M 26.71M Jun/2025
Genmab DKK 376M 172M Jun/2025
Geron USD -7550000 8.85M Jun/2025
Gilead Sciences USD 3.4B 797M Jun/2025
Incyte USD 581.52M 358.87M Jun/2025
MacroGenics USD -33437000 17.35M Jun/2025
Novartis USD 6.17B 339M Jun/2025